Francisco Nascimento, MD
Interventional Cardiology · Delray Beach, FLNPI 1326333246
Payments from drug & device makers
Across 604 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$5K
- Abbott$2K
- Johnson & Johnson$1K
- Amgen$1K
- Novartis$1K
- AstraZeneca$817
- plus $6K from 28 others
What the payments were for
- Speaking & faculty fees$3,00018%
- Travel & lodging$9916%
- Food & beverage$12,49475%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 42 | $5,404 |
| Abbott | 67 | $1,531 |
| Johnson & Johnson | 56 | $1,123 |
| Amgen | 62 | $1,103 |
| Novartis | 72 | $1,063 |
| AstraZeneca | 42 | $817 |
| Pfizer | 29 | $700 |
| E.r. Squibb & Sons, L.L.C. | 42 | $596 |
| Boehringer Ingelheim | 30 | $578 |
| Medtronic(2 entities) | 18 | $410 |
| Esperion Therapeutics, Inc. | 20 | $352 |
| Novo Nordisk | 14 | $315 |
| Sanofi-aventis U.S. LLC | 17 | $315 |
| Boston Scientific | 10 | $313 |
| Merck | 16 | $308 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $293 |
| Heartflow, Inc. | 5 | $244 |
| Chiesi USA, Inc. | 11 | $190 |
| Elutia, Inc. | 3 | $185 |
| Cvrx, Inc. | 7 | $180 |
| Merz North America, Inc. | 1 | $108 |
| Astellas Pharma US Inc | 3 | $70 |
| Lilly USA, LLC | 3 | $70 |
| Atricure, Inc. | 3 | $65 |
| Lundbeck LLC | 3 | $62 |
| Abiomed | 1 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Cardiva Medical, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$414
- ECM Patch,Pouch$140
- FFRct$137
- Confirm Rx$129
- INVOKANA$114
- XARELTO$114
- XEOMIN$108
How this compares
$16,627 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 395 | $517,038 |
| XareltoRivaroxaban | 232 | $281,756 |
| EntrestoSacubitril/Valsartan | 158 | $222,740 |
| Repatha SureclickEvolocumab | 114 | $101,933 |
| JardianceEmpagliflozin | 52 | $76,239 |
| OzempicSemaglutide | 42 | $48,205 |
| FarxigaDapagliflozin Propanediol | 31 | $37,517 |
| BrilintaTicagrelor | 37 | $29,551 |
| MultaqDronedarone Hcl | 12 | $27,346 |
| NexlizetBempedoic Acid/Ezetimibe | 27 | $22,616 |
| Praluent PenAlirocumab | 22 | $10,774 |
| Bumetanide | 374 | $10,101 |
| Metoprolol Succinate | 575 | $8,055 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $7,543 |
| Valsartan | 212 | $7,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $700 | $517,038395 claims |
| Johnson & JohnsonXarelto | $1,123 | $281,756232 claims |
| NovartisEntresto | $1,063 | $222,740158 claims |
| Boehringer IngelheimJardiance | $578 | $76,23952 claims |
| AstraZenecaFarxiga, Brilinta | $817 | $67,06868 claims |
| Novo NordiskOzempic | $315 | $48,20542 claims |
| Sanofi-aventis U.S. LLCMultaq | $315 | $27,34612 claims |
| Esperion Therapeutics, Inc.Nexlizet | $352 | $22,61627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Delray Beach
- Rodolfo Carrillo JimenezDelray Beach$384K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.